Mark Pruzanski, Versanis Bio CEO
July 20, 2022 07:00 AM EDTUpdated 07:42 AM
Startups
Bioregnum

Ex­clu­sive: Mark Pruzan­s­ki is once again reach­ing for the brass ring in biotech

Mark Pruzan­s­ki spent more than 18 years grow­ing In­ter­cept from a start­up to a com­mer­cial play­er look­ing for a land­mark ap­proval treat­ing NASH. But …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

Merus’ Phase 2 over­all sur­vival da­ta reach ‘home run’ sce­nario — an­a­lyst

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times